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Abstract Background
There are limited reports of thrombosis among myelodysplastic syndrome patients exposed to erythropoiesis stimulating agents. It is not clear whether erythropoiesis stimulating agents are associated with an increased risk of thrombosis in myelodysplastic syndromes, as they are among patients with solid tumors.
Design and Methods
The association between use of erythropoiesis stimulating agent and transient thrombosis risk in patients with myelodysplastic syndromes was assessed in a casecrossover study nested within a cohort of incident myelodysplastic syndromes patients.
Using the U.S. Surveillance, Epidemiology, and End Results Medicare-linked database, cases with an incident diagnosis of deep vein thrombosis were identified. Using conditional logistic regression, the odds of exposure to erythropoiesis stimulating agents in the 12 weeks prior to the incident deep vein thrombosis (hazard period) was compared to the exposure odds in a prior 12-week comparison period.
Results
Within the cohort of myelodysplastic syndromes (n=7,385) there were 212 incident cases of deep vein thrombosis, the mean age was 76.2 (standard deviation=+8. 6) years. Use of erythropoiesis stimulating agents was not associated with deep vein thrombosis in the crude nor the adjusted models (OR adj =1.21, 95% CI: 0.60, 2.43).
Central venous catheter placement (OR adj =6.47, 95% CI: 2.37, 17.62) and red blood cell transfusion (OR adj =4.60, 95% CI: 2.29, 9.23) were associated with deep vein thrombosis.
Introduction
The erythropoiesis-stimulating agents (ESA) epoetin alfa (Epogen; shown not only increases in the risk of tumor promotion and/or mortality, but also a significant (RR < 2.0) increase in the risk of venous thromboembolism (VTE) among patients randomized to receive ESAs, compared to placebo. [2] [3] [4] [5] [6] [7] Increased risk of thrombotic events was also reported among ESA users with chronic kidney failure and among patients preparing to for major surgery. weeks of therapy. 15 In the single fatal case, the patient had a prior history of DVT.
Hemoglobin levels rose significantly (>1 g/dl) in three patients in the trial, but only one of these three developed DVT. treated with lenalidomide, with a cumulative incidence of 3.4% for the first VTE event.
Of note, ESA users were excluded from the analyses in that study. 17 Since the widespread adoption of ESAs to treat MDS-associated anemia, there has been little published on the risk of thrombosis in this patient population. Here, a large administrative database was examined to determine if the use of ESAs in MDS patients is associated with an increased risk of VTE.
Design and Methods
Study population
Patients with MDS were identified in the National Cancer Institute's Surveillance 
Case definition
Patients were considered as cases based on a diagnosis of a deep vein thrombosis (DVT) during an outpatient visit or a hospitalization within the study period. The event date was set at the week of the first (incident) DVT following the diagnosis of MDS. In a sensitivity analysis, we also included patients who had an incident pulmonary embolism (PE) as cases.
The case-crossover design is a variation on the case-control design, in which a case serves as his/her own control. This study design is suitable for the study of transient outcomes that are believed to occur in close temporal proximity to the exposure. 
Drug exposure
Exposure was calculated separately for the hazard and comparison periods. The exposure of interest was the use of an ESA (erythropoietin alpha or darbepoietin alpha).
Weekly exposure measures were calculated based on one or more claims for either of these agents. Any exposure (yes/no) was defined as one or more claims for either agent during the 12-week period. Any exposure was also determined for the individual agents. Because darbepoietin alpha is longer-acting than erythropoietin alpha, its recommended dosing schedule is different. Therefore, cumulative exposure was calculated separately for each agent, defined as the sum of the weeks in which there was one or more claim for that agent within the 12-week period.
Covariates
Demographic characteristics of the patients were abstracted from the SEER database and conditioned on the date of the incident MDS diagnosis. These variables include patient age, gender, race, marital status, and the region of the country where they resided. A one-year look-back period from the date of MDS diagnosis was used to determine past medical history based on Medicare claims. A prior medical history was defined as either one inpatient claim with a date of service within the look-back period, or two outpatient claims (29 to 365 days apart) at least one of which was within the lookback period.
Because each person serves as his/her own control, static factors such as gender, medical and family history, underlying risk factors and, to some extent, age are matched between cases and controls. Only factors that change over the study period can be evaluated for their temporal association with DVT risk. These transient covariates included the use of granulocyte colony-stimulating factor (G-CSF) and chemotherapy.
Unlike oral drugs, these drugs are covered under Medicare part B and can be identified through procedure codes specific to their administration. Patients were also classified based on the presence or absence of an inpatient hospitalization, red blood cell transfusion, platelet transfusion, and central venous catheter placement during the hazard and comparison periods.
Statistical aanalysis
The MDS patients who had an incident DVT during follow-up were characterized based on their baseline characteristics and past medical history. Among these cases, the proportion of patients who had an ESA exposure, transfusions, and other key exposures and events were compared between the hazard and comparison periods using Chi- 
Results
Patients' characteristics
A total of 5,673 MDS patients met eligibility criteria for this study, among whom 212 had an incident DVT within the required time frame. Among the 212 incident DVT cases, the most common type of MDS was the category 'not otherwise specified' (49.1%), followed by refractory anemia (RA) (19.9%) and refractory anemia with ringed sideroblasts (RARS) (13.7%), with only 20 cases (9.4%) categorized as refractory anemia with excess blasts (RAEB) ( Table 1 ). The majority of patients (46.7%) were 75-84 years of age at diagnosis of MDS, with approximately equal distributions of males and females.
As might be expected given the age distribution, there was a high prevalence of chronic conditions. Within the year prior to their MDS diagnosis, 36.8% of the DVT patients had a health care service claim with a diagnosis of ischemic heart disease. High rates of congestive heart failure (21.7%), diabetes (22.2%) and chronic obstructive pulmonary disease (COPD) (21.7%) were also noted. Thirty patients (14.2%) had a history of cancer prior to their diagnosis of MDS.
There were similar rates of ESA utilization in the hazard period and the comparison period (44.8% versus 41.5%) ( Table 2 ). The length of exposure was similarly 
Thombosis risk factors
In the crude conditional logistic regression model, the odds ratio (OR) for ESA use was slightly elevated, but did not vary significantly between time periods (OR=1.37, 95%
CI:0.76, 2.47) ( Table 3) 
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